Risk-ben­e­fit de­ter­mi­na­tions: FDA fi­nal­izes long-await­ed guid­ance for drug­mak­ers

The FDA on Thurs­day fi­nal­ized guid­ance from Sep­tem­ber 2021 on the agency’s ben­e­fit-risk as­sess­ments for new drugs and bi­o­log­ics, spelling out its most per­ti­nent con­sid­er­a­tions in de­ter­min­ing whether a new ap­pli­ca­tion’s ben­e­fits out­weigh the risks.

The 23-page guid­ance, cre­at­ed as part of FDA’s 21st Cen­tu­ry Cures Act com­mit­ments, of­fers high-lev­el thoughts on how a drug’s ben­e­fits, risks, and risk man­age­ment fac­tor in­to FDA’s pre- and post-mar­ket reg­u­la­to­ry de­ci­sions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER